Cytotoxicity of allitinib, an irreversible anti-EGFR agent, in a large panel of human cancer-derived cell lines: KRAS mutation status as a predictive biomarker.

导出 LinkOut

翻译打印收藏纠错

作者： Renato José,Silva-Oliveira ^[1] ; Viviane Aline Oliveira,Silva ^[1] ; Olga,Martinho ^[1] ; Adriana,Cruvinel-Carloni ^[2] ; Matias Eliseo,Melendez ^[3] ; Marcela Nunes,Rosa ^[1] ; Flávia Escremim,de Paula ^[1] ; Luciano,de Souza Viana ^[1] ; André Lopes,Carvalho ^[1] ; Rui Manuel,Reis ^[1]

作者单位： Molecular Oncology Research Center, Barretos Cancer Hospital, Rua Antenor Duarte Villela, 1331, CEP 14784 400, Barretos, São Paulo, Brazil. ^[1] Life and Health Sciences Research Institute (ICVS), Health Sciences School, University of Minho, Braga, Portugal. ^[2] ICVS/3B's-PT Government Associate Laboratory, Braga, Guimarães, Portugal. ^[3] Department of Medical Oncology, Barretos Cancer Hospital, Barretos, São Paulo, Brazil. ^[4] Molecular Oncology Research Center, Barretos Cancer Hospital, Rua Antenor Duarte Villela, 1331, CEP 14784 400, Barretos, São Paulo, Brazil. ruireis.hcb@gmail.com. ^[5] Life and Health Sciences Research Institute (ICVS), Health Sciences School, University of Minho, Braga, Portugal. ruireis.hcb@gmail.com. ^[6] ICVS/3B's-PT Government Associate Laboratory, Braga, Guimarães, Portugal. ruireis.hcb@gmail.com. ^[7]

关键词 Allitinib EGFR inhibitor In vitro screening KRAS mutation